Pharmacoeconomics of combination antihypertensive therapy

Blood Pressure Monitoring

Volumn 6, Issue SUPPL. 1, 2001, Pages

  Hilleman, D E ^a  

^a CREIGHTON UNIVERSITY SCHOOL OF PHARMACY AND HEALTH PROFESSIONS   (United States)

Author keywords

Antihypertensive therapy; Cost effectiveness; Hypertension; Pharmacoeconomics

Indexed keywords

ANTIHYPERTENSIVE AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT;

COST BENEFIT ANALYSIS; COST EFFECTIVENESS ANALYSIS; DRUG EFFICACY; DRUG TOLERABILITY; HEALTH CARE COST; HEALTH ECONOMICS; HYPERTENSION; PRIORITY JOURNAL; REVIEW;

EID: 0035200252     PISSN: 13595237     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (28)

1. The benefits of lowering elevated blood pressure: A critical review of studies of cardiovascular morbidity and mortality in hypertension
2. The benefits of angiotensin II receptor blockers in patients with renal insufficiency or failure
3. Angiotensin receptor blockers in chronic renal disease: The promise of a bright clinical future
4. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: Principal results of the Hypertension Optimal Treatment (HOT) randomized trial
5. Choice of initial therapy for hypertension
6. Compliance with antihypertensive therapy: Raising the bar of expectations
7. Inadequate management of blood pressure in a hypertensive population
8. The majority of mild to moderate hypertensives require combination antihypertensive therapy: Preliminary results from BAHAMA study
9. Remembering the lessons of basic pharmacology
10. Combination products as first-line pharmacotherapy
11. Low-dose drug combination therapy: An alternative first-line approach to hypertension treatment
12. Single-drug therapy for hypertension in men: A comparison of six antihypertensive agents with placebo
13. Cost effectiveness of combination therapy
14. Cost savings associated with therapeutic interchange in the treatment of mild-to-moderate hypertension
15. Efficacy and safety of a therapeutic interchange from high-dose calcium channel blockers to fixed-dose combination of amlodipine/benazepril in patients with hypertension
16. Long-term cost-effectiveness of various initial monotherapies for mild-to-moderate hypertension
17. Cost-benefit of treating hypertension
18. The cost effectiveness of hypertension treatment in Sweden
19. Cost-effectiveness issues in hypertension control
20. Treatment of patients with essential hypertension: Amlodipine 5 mg/benazepril 20 mg compared with amlodipine 5 mg, benazepril 20 mg, and placebo
21. Comparison of amlodipine and benazepril monotherapy to amlodipine plus benazepril in patients with systemic hypertension: A randomized, double-blind, placebo-controlled, parallel-group study
22. Antihypertensive efficacy of a once a day verapamil-SR/trandolapril combination
23. Trandolapril and verapamil slow release in the treatment of hypertension: A dose-response assessment with the use of a multi-factorial trial design
24. Fixed-dose combination therapy vs monotherapy in hypertension: A meta-analysis evaluation
25. Losartan and low-dose hydrochlorothiazide in patients with essential hypertension. A double-blind, placebo-controlled trial of concomitant administration compared with individual components
26. Usefulness of combination therapy in hypertensive patients who do not respond to an angiotensin type 1 receptor antagonist alone
27. Angiotensin II receptor antagonist plus a thiazide diuretic is more efficacious for treating hypertension than either drug alone